Diclofenac Drops for Corneal Abrasion Pain
Yes, topical diclofenac (and other NSAIDs) should be used for corneal abrasion pain control, as they provide effective analgesia in the first 48 hours and reduce the need for oral pain medications by approximately 50%.
FDA-Approved Indication
The FDA label for diclofenac ophthalmic solution explicitly approves its use for "temporary relief of pain and photophobia in patients undergoing corneal refractive surgery" 1. While traumatic corneal abrasions are not specifically listed, the mechanism of pain (epithelial disruption) is identical, and the evidence strongly supports this off-label use.
Evidence for Pain Control
Efficacy at 24 and 48 Hours
Topical NSAIDs, including diclofenac, demonstrate significant pain reduction compared to placebo or standard care:
- At 24 hours: Pain scores reduced by standardized mean difference of -0.69 (95% CI -0.98 to -0.41) 2
- At 48 hours: Pain scores reduced by standardized mean difference of -0.56 (95% CI -1.02 to -0.10) 2
- Rescue analgesia: 53% reduction (95% CI 34% to 67%) in oral analgesic use compared to control 2
A specific study on diclofenac showed a 2.1-point greater improvement on the pain scale at 2 hours compared to vehicle control (95% CI 0.8 to 3.4), with significantly fewer patients requiring rescue oxycodone-acetaminophen 3.
Clinical Impact
In one study combining diclofenac with bandage contact lens, 80% of patients were able to immediately return to work, including 93% of those with small abrasions (<10 mm²) 4. This demonstrates meaningful functional improvement beyond just pain scores.
Safety Profile
Healing and Complications
Critical finding: No intervention, including topical NSAIDs, resulted in healing delays or significantly higher complication rates compared to controls in simple, uncomplicated corneal abrasions 2.
- Complications were rare overall (4 total complications across 609 participants in 6 studies) 2
- One recurrent corneal erosion in NSAID group vs. two recurrent erosions and one corneal abscess in control groups 5
- Adverse events were minimal: transient mild stinging, occasional conjunctival hyperemia 3
Important Caveats
The evidence specifically applies to simple traumatic corneal abrasions. You must exclude:
- Contact lens-related abrasions (higher infection risk)
- Signs of infection or infiltrate
- Deep or complicated abrasions
- Recurrent erosion syndrome
- Patients with compromised healing (severe dry eye, neurotrophic keratopathy)
Practical Dosing Regimen
Based on FDA labeling for similar indications 1:
- Initial dose: 1-2 drops immediately after diagnosis
- Maintenance: 1 drop four times daily
- Duration: Up to 3 days (similar to corneal refractive surgery protocol)
- Always combine with: Topical antibiotic prophylaxis
Comparison to Alternative Analgesics
Topical Anesthetics
Recent consensus guidelines suggest short-term topical anesthetics (proparacaine, tetracaine) may be safe for 24 hours 6, but the evidence remains limited and controversial. NSAIDs are the better-established option with more robust safety data 2, 5.
Oral Analgesics Alone
While oral NSAIDs or opioids can be used, topical NSAIDs provide direct local effect with minimal systemic absorption, making them preferable as first-line therapy. They reduce the need for oral opioids by half 2.
Clinical Algorithm
For simple traumatic corneal abrasion:
- Confirm diagnosis: Fluorescein staining, rule out foreign body, no signs of infection
- Initiate treatment:
- Topical antibiotic (e.g., erythromycin ointment or fluoroquinolone drops)
- Diclofenac 0.1% drops: 1 drop QID for 2-3 days
- Consider bandage contact lens for larger abrasions (>10 mm²) with close follow-up
- Rescue analgesia: Oral acetaminophen or NSAIDs as needed
- Follow-up: 24-48 hours to confirm healing
Avoid diclofenac if:
- Contact lens-related abrasion
- Signs of infection present
- Known NSAID allergy
- Chronic/recurrent erosions
- Compromised corneal healing capacity
Strength of Recommendation
The evidence supporting topical NSAIDs is low certainty per GRADE criteria 2, 5, primarily due to heterogeneity in study designs and small sample sizes. However, the consistent direction of effect across multiple studies, combined with the excellent safety profile and FDA approval for similar indications, makes this a reasonable and widely accepted clinical practice.
The 2021 systematic review and meta-analysis provides the strongest synthesis of evidence, concluding that topical NSAIDs are the only intervention with adequate evidence supporting pain reduction in corneal abrasions 2.